Erste Asset Management GmbH Purchases 1,064,530 Shares of Sarepta Therapeutics, Inc. $SRPT

Erste Asset Management GmbH boosted its position in shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT) by 65.7% in the third quarter, Holdings Channel reports. The firm owned 2,685,945 shares of the biotechnology company’s stock after purchasing an additional 1,064,530 shares during the period. Erste Asset Management GmbH’s holdings in Sarepta Therapeutics were worth $50,588,000 at the end of the most recent quarter.

Several other hedge funds also recently bought and sold shares of the company. Sound View Wealth Advisors Group LLC boosted its position in shares of Sarepta Therapeutics by 6.1% during the third quarter. Sound View Wealth Advisors Group LLC now owns 12,695 shares of the biotechnology company’s stock worth $245,000 after purchasing an additional 728 shares in the last quarter. Clearstead Advisors LLC raised its stake in Sarepta Therapeutics by 27.5% during the 3rd quarter. Clearstead Advisors LLC now owns 12,369 shares of the biotechnology company’s stock worth $238,000 after buying an additional 2,669 shares during the period. Vanguard Group Inc. lifted its holdings in Sarepta Therapeutics by 18.1% during the third quarter. Vanguard Group Inc. now owns 10,817,446 shares of the biotechnology company’s stock worth $208,452,000 after acquiring an additional 1,657,267 shares in the last quarter. PNC Financial Services Group Inc. lifted its holdings in Sarepta Therapeutics by 87.3% during the third quarter. PNC Financial Services Group Inc. now owns 7,078 shares of the biotechnology company’s stock worth $136,000 after acquiring an additional 3,299 shares in the last quarter. Finally, Aberdeen Group plc grew its stake in Sarepta Therapeutics by 59.6% in the third quarter. Aberdeen Group plc now owns 1,982,764 shares of the biotechnology company’s stock valued at $38,208,000 after acquiring an additional 740,360 shares during the period. 86.68% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling at Sarepta Therapeutics

In other news, COO Ian Michael Estepan sold 13,187 shares of the firm’s stock in a transaction dated Tuesday, December 16th. The stock was sold at an average price of $22.31, for a total value of $294,201.97. Following the completion of the transaction, the chief operating officer owned 193,300 shares in the company, valued at $4,312,523. This trade represents a 6.39% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. 7.60% of the stock is owned by insiders.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently commented on SRPT shares. Weiss Ratings reaffirmed a “sell (d)” rating on shares of Sarepta Therapeutics in a research report on Monday, December 29th. Wedbush raised their target price on shares of Sarepta Therapeutics from $32.00 to $34.00 and gave the stock an “outperform” rating in a report on Friday, January 23rd. Mizuho raised shares of Sarepta Therapeutics from a “neutral” rating to an “outperform” rating and lifted their price target for the company from $19.00 to $26.00 in a research note on Wednesday, November 5th. HC Wainwright reissued a “sell” rating on shares of Sarepta Therapeutics in a research report on Tuesday, January 27th. Finally, Royal Bank Of Canada raised their price objective on shares of Sarepta Therapeutics from $16.00 to $18.00 and gave the stock a “sector perform” rating in a report on Thursday, January 8th. Nine research analysts have rated the stock with a Buy rating, thirteen have assigned a Hold rating and six have issued a Sell rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of “Hold” and an average price target of $33.84.

Sarepta Therapeutics Price Performance

NASDAQ SRPT opened at $17.45 on Friday. The firm’s 50 day moving average is $20.51 and its 200-day moving average is $20.22. The company has a quick ratio of 1.79, a current ratio of 2.95 and a debt-to-equity ratio of 0.78. The company has a market capitalization of $1.83 billion, a PE ratio of -2.07, a price-to-earnings-growth ratio of 0.48 and a beta of 0.39. Sarepta Therapeutics, Inc. has a 12-month low of $10.41 and a 12-month high of $109.50.

Sarepta Therapeutics (NASDAQ:SRPT) last announced its earnings results on Wednesday, February 25th. The biotechnology company reported ($3.58) EPS for the quarter, missing the consensus estimate of ($0.87) by ($2.71). Sarepta Therapeutics had a negative return on equity of 49.42% and a negative net margin of 38.34%.The business had revenue of $442.93 million for the quarter, compared to analyst estimates of $390.95 million. During the same quarter in the previous year, the company posted $1.90 EPS. The business’s revenue for the quarter was down 32.7% compared to the same quarter last year. Equities research analysts anticipate that Sarepta Therapeutics, Inc. will post 2.67 earnings per share for the current fiscal year.

Sarepta Therapeutics News Roundup

Here are the key news stories impacting Sarepta Therapeutics this week:

• Positive Sentiment: Revenue topped Street estimates, showing better-than-expected top-line performance for the quarter despite product-specific weakness. Sarepta Q4 Loss Wider Than Expected, Sales Beat Estimates
• Positive Sentiment: Management emphasized a solid balance sheet and cash position on the call/press release, which can support R&D and the transition period. Press Release: Q4 and Full-Year 2025 Financial Results
• Positive Sentiment: New longer-term and safety data will be presented at the MDA Clinical & Scientific Congress, offering potential catalysts if data are favorable. MDA Conference Presentation Announcement
• Neutral Sentiment: Full earnings materials and the call transcript/slides are available for investors to review management’s details on costs, cash burn and product strategies. Earnings Slides / Press Release
• Negative Sentiment: Earnings per share missed badly: SRPT reported a loss of $3.58/share vs. consensus around a $0.87 loss, a large downside surprise that pressured the stock. MarketBeat Q4 Summary
• Negative Sentiment: Elevidys sales “tumbled,” driving much of the revenue decline vs. prior year and signaling market-share and demand challenges for Sarepta’s key product. Zacks: Sales Beat but Elevidys Sales Tumble
• Negative Sentiment: Revenue declined ~33% year-over-year, underscoring that the company is in a down cycle and must show steady recovery to restore investor confidence. Yahoo Finance: Compared to Estimates
• Negative Sentiment: CEO Douglas Ingram announced he will retire by year-end (or upon replacement), creating near-term leadership uncertainty during a critical turnaround period. Reuters: CEO to Retire
• Negative Sentiment: Company issued cautious 2026 guidance, signaling recovery will be gradual — investors typically punish biotech names that lower near-term visibility into growth. Yahoo Finance: Guidance and Recovery Path

Sarepta Therapeutics Company Profile

Sarepta Therapeutics, Inc is a biopharmaceutical company focused on the discovery and development of precision genetic medicines for rare neuromuscular diseases. Headquartered in Cambridge, Massachusetts, Sarepta’s core expertise lies in designing RNA-targeted therapies and gene therapies that address underlying genetic mutations. The company’s mission is to transform the treatment paradigm for patients with Duchenne muscular dystrophy (DMD) and related disorders through innovative modalities.

Sarepta’s commercial products include several exon-skipping therapies approved by the U.S.